Drug profile · INN
lisocabtagene maraleucel
BREYANZI
lisocabtagene maraleucel (BREYANZI) is a b-lymphocyte antigen cd19 binding agent.
Drug details — lisocabtagene maraleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
lisocabtagene maraleucel (BREYANZI) is a b-lymphocyte antigen cd19 binding agent.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Medicare Coverage CAR-T Therapies: Policy Changes & Patient Impact 2024
This article discusses the 2024 Medicare policy changes regarding CAR-T therapies, highlighting their implications for patients with blood cancers.
FDA Approves Breyanzi: Novel CAR-T Therapy for Mantle Cell Lymphoma
Breyanzi has received FDA approval as a novel CAR-T therapy, providing a promising treatment option for patients with mantle cell lymphoma.
CHMP Positive Opinion CAR-T Therapy: What You Need to Know
The CHMP has issued a positive opinion for CAR-T therapy, a groundbreaking treatment for specific blood cancers, offering new hope for patients.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lisocabtagene maraleucel?
lisocabtagene maraleucel (BREYANZI) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for lisocabtagene maraleucel?
BREYANZI is a marketed brand name for lisocabtagene maraleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.